Key facts
- This page summarizes DRAGSA 96 LLC's Form 3 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 21 Jan 2022, 16:10.
Key filing fact
Ownership activity is grounded in SEC Form 3 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
No transaction description listed
Additional SEC filing notes
Footnote F1
The following persons affiliated with DRAGSA 96 LLC separately reported these securities on Form 4 filed January 13, 2022: Andreas Halvorsen, David C. Ott, Rose S. Shabet, Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, and Viking Global Opportunities Illiquid Investments Sub-Master LP.
SEC remarks
(2) Scott M. Hendler is signing on behalf of Mr. Halvorsen, Mr. Ott and Ms. Shabet, each as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, as manager of DRAGSA 96 LLC, pursuant to authorization and designation letters dated February 9, 2021, which were filed with the Securities and Exchange Commission on June 7, 2021.